Table 2.
Steady-state pharmacokinetic parameters for linezolid concentrations in plasma and tissue samplesa
| Parameterb | Result for indicated sample typec |
P valued (n = 7) | ||
|---|---|---|---|---|
| Plasma (n = 9) | Wound tissue (n = 9) | Thigh tissue (n = 7) | ||
| Cmax (μg/ml) | 11.99 ± 3.67e | 13.45 ± 8.61 | 14.4 ± 7.49 | 0.714 |
| Tmax (h) | 1e | 2.11 ± 0.33 | 2.57 ± 0.79 | 0.289 |
| AUC0–12 (μg · h/ml) | 68.76 ± 29.31 | ND | ND | |
| ƒAUC0–12 (μg · h/ml) | 51.24 ± 12.72f | 82.76 ± 59.01 | 92.52 ± 60.44 | 0.942 |
| t1/2 (h) | 4.71 ± 1.23 | 5.14 ± 1.48 | 4.69 ± 1.78 | 0.275 |
| CL (liter/h/kg) | 0.11 ± 0.04 | ND | ND | |
| Vz (liter/kg) | 0.71 ± 0.25 | ND | ND | |
a
Steady state was achieved following 3 to 4 600-mg doses of linezolid administered as intravenous infusions for 1 h every 12 h.
b
Cmax, maximum concentration of linezolid; CL, clearance.
c
Values are reported as means ± standard deviations. ND, not determined.
d
The P value was obtained by comparing results for wound and thigh tissues.
e
Two subjects were excluded from this analysis (n = 7), as one subject received a 2-h infusion and another subject's concentration data at 1 h was not evaluable due to sample contamination.
f
Protein binding data were not available for one subject (n = 8).